NewsRx

Search our medical news database

Acute Peripheral Arterial Occlusion

European Medicines Agency grants orphan drug designation for alfimeprase

Published in Cardiovascular Week, December 5th, 2005

Nuvelo Inc. (NUVO) announced that it has obtained orphan drug designation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA) for its lead product candidate, alfimeprase, for the treatment of acute peripheral arterial occlusion (PAO), or leg attack.

The designation provides sponsors with several benefits, including protocol development assistance and a 10-year period of market exclusivity following market authorization. Nuvelo has already obtained orphan drug designation from the Office of Orphan Products Development at the U.S. Food and Drug Administration (FDA) for alfimeprase for the treatment of acute PAO.

...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook